The safety and efficacy of cisatracurium 0.15 mg.kg(-1) during nitrous oxide-opioid anaesthesia in infants and children

We studied the neuromuscular and cardiovascular effects of a single, rapidl y administered intravenous dose of cisatracurium 0.15 mg.kg(-1) in 27 infan ts (aged 1-23 months) and 24 children (aged 2-12.5 years). After midazolam premedication, anaesthesia was induced and maintained with thiopental and a lfentanil in addition to nitrous oxide in oxygen. Neuromuscular function wa s monitored by evoked adductor pollicis electromyography. At least 15 min a fter intubation, each patient received cisatracurium 0.15 mg.kg(-1) over 5 s. Complete neuromuscular blockade was produced by this dose in all but one infant. The mean (SD) onset time of maximal blockade was more rapid in inf ants [2.0 (0.8) min] than in children [3.0 (1.2) min], p = 0.0011. The clin ical duration of action of cisatracurium (recovery of evoked response to 25 % of control) was significantly longer in infants [43.3 (6.2) min] than in children [36.0 (5.4) min], p < 0.0001. Once neuromuscular function started to recover, the rate of recovery was similar in both age groups. Changes in blood pressure and heart rate after the administration of cisatracurium we re negligible in both age groups. Cisatracurium, at a dose of 0.15 mg.kg(-1 ), was effective and well tolerated in infants and children.